Chris Lange

Chris Lange is an analyst for 24/7 Wall St., based in Houston. He has covered financial markets over the past five years with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and has helped start a small business.

Lastest Stories by Chris Lange

The tale of the tape was drastically different when JPMorgan and Wells Fargo reported quarterly results, and this was reflected somewhat in what analysts are saying about them after the fact.
Immutepjoins the ever-growing list of coronavirus stocks by announcing that it was granted a patent related to COVID-19 antibodies.
Moderna made another big step forward in the fight against COVID-19 after the company reported incredibly positive data from the early-stage trial of its coronavirus vaccine.
UnitedHealth Group released mixed second-quarter financial results and maintained its guidance before the markets opened on Wednesday.
24/7 Wall St. looks at some potential winners among Warren Buffett’s holdings. See why they could rally headed toward 2021 and beyond.
IMV shares surged on Tuesday after the company provided an update on its vaccine candidate for COVID-19.
American Airlines may be joining the list of companies that are furloughing employees during this coronavirus pandemic.
Blueprint Medicines announced early on Tuesday that it had entered into a global collaboration with pharmaceutical giant Roche in which it may receive up to $1.7 billion.
Citigroup reported better than expected second-quarter financial results before the markets opened on Tuesday.
Wells Fargo released a disappointing second-quarter earnings report and lowered its dividend before the opening bell on Tuesday.
24/7 Wall St. has picked out a handful of stocks that are the biggest winners from the pandemic thus far. Analysts are incredibly bullish on them all.
One of the most important aspects of reopening the economy during this pandemic is testing for COVID-19. Credit Suisse sees a couple of winners benefitting incredibly from this.
Pfizer and BioNTech have progressed in their COVID-19 vaccine effort, according to the FDA. Two of the companies’ four coronavirus vaccine candidates received Fast Track Designation.
PepsiCo reported better than expected most recent quarterly results before the markets opened on Monday but noted that its fiscal 2020 guidance is no longer applicable.
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.